following a full submission
sacubitril/valsartan (Entresto®) is accepted for use within NHS Scotland.
Indication under review: in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
Sacubitril/valsartan, compared to an angiotensin-converting enzyme inhibitor, significantly reduced rates of the composite outcome of cardiovascular death and hospitalisation for heart failure, rates of the component outcomes and of all cause mortality.
|Drug Name:||sacubitril/valsartan (Entresto)|
|SMC Drug ID:||1132/16|
|Manufacturer:||Novartis Pharmaceuticals UK Ltd|
|Indication:||In adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.|
|Sub Category:||2.5 Hypertension and heart failure|
|Submission Type:||Full submission|
|Date Advice Published:||7 March 2016|